Clinical Trials Logo

Critically Ill clinical trials

View clinical trials related to Critically Ill.

Filter by:

NCT ID: NCT01126554 Completed - Critically Ill Clinical Trials

ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill Patients

Greenpep
Start date: July 2010
Phase: N/A
Study type: Observational

Comparison of ICG liver testing with copeptin and SAPS II score as prognostic markers in critically ill patients.

NCT ID: NCT01102348 Completed - Critically Ill Clinical Trials

Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients

PEP-uP
Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to assess the feasibility, acceptability, and safety of a new feeding protocol, "The Enhanced Protein-Energy Provision via the Enteral Route in Critically Ill Patients: The PEP uP protocol."

NCT ID: NCT01091233 Withdrawn - Liver Cirrhosis Clinical Trials

The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study

Start date: March 2010
Phase:
Study type: Observational

Patients with liver cirrhosis are at risk for development of renal failure, usually after a precipitating event such as infection or bleeding. This form of renal failure has a high morbidity and mortality and may be partly caused by increased intra-abdominal pressure secondary to ascites. Recent studies have shown that paracentesis (and the resulting decreased IAP) can increase urinary output and decrease renal arterial resistive index in patients with hepatorenal syndrome (a very pronounced form of renal failure in cirrhosis patients). The aim of this study is to evaluate the influence of Paracentesis on intra-abdominal pressure and kidney function in critically ill patients with liver cirrhosis and ascites across a wider range of kidney function. Kidney function will be evaluated using several estimates of glomerular filtration rate and measures of kidney injury i.e. cystatin C, serum NGAL, creatinine clearance, urinary output and renal arterial resistive index.

NCT ID: NCT01090791 Terminated - Critically Ill Clinical Trials

FLOTRAC/VIGILEO in Acute Circulatory Failure

FLOVAC
Start date: May 2011
Phase: N/A
Study type: Observational

Acute circulatory failure may be related to hypovolemia. Fluid loading increases stroke volume in approximatively half of challenges. Determining fluid responsiveness prevents unnecessary fluid loading. Passive leg raising (PLR) provides a transient increase of 300 ml in venous return for a short time. The measurement of stroke volume (SV) before and after a PLR test allows physician to detect fluid responsiveness, when stroke volume increases is higher than 15 %. Beside thermodilution, the use of non invasive device to measure stroke volume becomes largely employed. Arterial Pressure based Cardiac Output (APCO), provided by the Flotrac/Vigileo system, does not required specific materials nor repeated calibration. The third generation software is believed to be more accurate and more precise for SV measurement. The aim of this study is to test the performance of the Flotrac/Vigileo device in a situation of rapid venous return changes induced by PLR and then by fluid loading. Patients will be classify posteriorly in responders and non responders, according to the magnitude of the fluid loading-induced SV changes measured by transthoracic echocardiography.

NCT ID: NCT01085071 Completed - Cardiac Surgery Clinical Trials

Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients

GRIP-COMPASS
Start date: June 2009
Phase: Phase 4
Study type: Interventional

Rationale: It is well known that distinctly abnormal blood potassium values can cause serious complications such as cardiac arrhythmias. Although potassium regulation is generally considered important, hardly any research has been done about potassium regulation in intensive care patients. The investigators hypothesize that different potassium target-values, within the as normal accepted range, may have different effects in critically ill patients. Study design: A prospective trial comparing two different potassium target-values. Potassium will be tightly regulated with the already fully operational GRIP-II computer program. Study population: 1200 adult patients admitted at the thoracic intensive care unit of the University Medical Center Groningen. Intervention: Comparison between two variations of standard therapy: potassium target-value of 4.0 mmol/L versus 4.5 mmol/L. Main study parameters/endpoints: The primary endpoint is the incidence of atrial fibrillation or atrial flutter from ICU-admission to hospital discharge. Secondary endpoints are serum levels of potassium and the other main electrolytes, renal function and renal potassium excretion, the relation with insulin and glucose, the cumulative fluid balance, (ICU) length of stay and mortality.

NCT ID: NCT01082666 Completed - Critically Ill Clinical Trials

Continuous Control of Tracheal Cuff Pressure and Microaspiration in Critically Ill Patients

Start date: October 2009
Phase: Phase 4
Study type: Interventional

We hypothesized that continuous control of tracheal cuff pressure would reduce microaspiration of gastric content as determined by pepsin level in tracheal aspirate.

NCT ID: NCT01077895 Withdrawn - Acute Kidney Injury Clinical Trials

The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function

Start date: February 2010
Phase: Phase 3
Study type: Interventional

Intra- abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) are a cause of organ dysfunction in critically ill patients. IAH develops due to abdominal lesions (primary IAH) or extra-abdominal processes (secondary IAH). Secondary IAH arises due to decreased abdominal wall compliance and gut edema caused by capillary leak and excessive fluid resuscitation. Decreasing intra-abdominal pressure (IAP) using decompressieve laparotomy has been shown to improve organ dysfunction. However, laparotomy is generally avoided in patients with secondary IAH due to the risk of abdominal complications. Acute kidney injury (AKI) is one of the first and most pronounced organ failures associated with IAH and many patients with AKI in the ICU require renal replacement therapy (RRT). Fluid removal using continuous RRT (CRRT) has been demonstrated to decrease IAP in small series and selected patients. The aim of this study is to evaluate whether fluid removal using CVVH in patients with IAH, fluid overload and AKI is feasible and whether it has a beneficial effect on organ dysfunction (compared to CVVH without net fluid removal).

NCT ID: NCT01047267 Completed - Critically Ill Clinical Trials

Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)

Start date: June 2010
Phase: N/A
Study type: Observational

The objective of this study is to determine whether pharmacokinetic parameters of anidulafungin correlate with disease severity and plasma protein levels in critically ill patients.

NCT ID: NCT01038622 Completed - Critically Ill Clinical Trials

Directed Immuno Nutrition by L-arginine for Critically Ill Patients

Immunolarg
Start date: November 2009
Phase: Phase 4
Study type: Interventional

The main objective of this proof-of-concept study is to demonstrate that the only administration of L-arginine, based on a suspected deficit monitored by nasal nitric oxide measurement, can improve immune functions in critically ill patients at high risk of nosocomial infection.

NCT ID: NCT01033955 Terminated - Critically Ill Clinical Trials

Collaborative H1N1 Adjuvant Treatment Pilot Trial

CHAT
Start date: January 2010
Phase: Phase 2
Study type: Interventional

Study Design: A, multinational, double blind, placebo-controlled pilot RCT involving 80 patients in the general ICUs of 30 centres. Most patients will be recruited from within Canada; however cases will be recruited from international sites. This study will be conducted under the auspices of the Canadian Critical Care Trials Group (CCCTG) and the International Forum for Acute Care Trialists (InFACT).